Moderna Settles Patent Dispute with Arbutus and Genevant
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy MRNA?
Source: seekingalpha
- Patent Settlement Agreement: Moderna has agreed to pay $950 million to settle a patent dispute with Arbutus Biopharma and Genevant Sciences, removing a significant legal overhang that is expected to boost market confidence in the company.
- Potential Additional Liability: Under the agreement, Moderna may face up to an additional $1.3 billion payment within 90 days depending on the Federal Circuit's ruling, introducing a layer of uncertainty that could impact its future financial performance.
- Positive Analyst Sentiment: Citi analysts believe the deal alleviates negative pressure on the stock, noting that while it is not the best-case scenario, it is better than feared, with William Blair analysts also viewing it as a positive clearing event.
- Reduced Litigation Costs: J.P. Morgan analysts highlight that the maximum $2.3 billion Moderna must pay is significantly lower than the previously estimated $5 billion, demonstrating effective cost control in the settlement that may contribute to the company's future financial stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 54.590
Low
17.00
Averages
32.47
High
63.00
Current: 54.590
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MODERNA: EC APPROVES MARKETING AUTHORIZATION FOR MRNA-1083 FOR PEOPLE AGED 50 AND ABOVE
- Moderna's Authorization: Moderna has received market authorization for its mRNA-1083 vaccine for individuals aged 50 years and older.
- Target Demographic: The vaccine is specifically aimed at older adults, addressing their unique health needs.
See More
MODERNA: MCOMBRIAX TO BE RELEASED IN THE EUROPEAN UNION, PENDING NATIONAL REGULATORY AND ACCESS REQUIREMENTS
Availability in Europe: Moderna's new vaccine, MCOMBRIAX, will be made available in the European Union.
Regulatory Compliance: The vaccine's release is subject to national regulatory and access procedures.
See More
MODERNA'S MRNA COMBINATION VACCINE MCOMBRIAX APPROVED FOR MARKETING BY EUROPEAN COMMISSION FOR INFLUENZA AND COVID-19
Marketing Authorization Granted: Moderna has received marketing authorization from the European Commission for its mRNA combination vaccine, Combrixa.
Targeted Diseases: The vaccine is designed to protect against both influenza and COVID-19.
See More
Moderna's mCOMBRIAX Vaccine Receives EU Approval
- Vaccine Approval: Moderna's mCOMBRIAX (mRNA-1083) vaccine has received marketing authorization from the European Commission, targeting both COVID-19 and influenza, particularly for individuals aged 50 and older, marking a significant advancement in the company's vaccine development efforts.
- Broad Coverage: The approval applies across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway, indicating its wide applicability in the European market and is expected to significantly enhance Moderna's competitiveness in the vaccine sector.
- Expert Recommendation: This approval follows a recommendation from an expert panel of the European Medicines Agency (EMA) in February, reflecting the vaccine's scientific efficacy and safety, thereby laying a solid foundation for Moderna's future sales.
- Market Launch Plans: Moderna stated it will engage with national healthcare officials to plan the launch of mCOMBRIAX in the EU, although the specific timeline will depend on local regulatory and access procedures, a strategy that will impact its market penetration in Europe.
See More
Investment Opportunities in Biotech Stocks
- Moderna's Innovative Potential: Moderna's mRNA vaccine platform allows for faster vaccine design compared to traditional methods, which could drive long-term returns, especially given the increased uncertainty in the COVID-19 vaccine market, where the company's deep pipeline and innovative technology may yield significant investment returns.
- Diverse Pipeline Products: Moderna is developing a vaccine for norovirus and a personalized cancer vaccine, mRNA-4157, which has shown significant potential in mid-stage trials to reduce recurrence and death risk in melanoma patients, further enhancing its market competitiveness.
- Regeneron's Market Leadership: Regeneron's Dupixent is a top-selling drug globally, particularly after gaining important label expansions for COPD treatment, expected to continue driving sales growth, while its high-dose Eylea offers a more patient-friendly dosing regimen, attracting patients despite biosimilar competition.
- Diversified Product Pipeline: Regeneron is developing products across various therapeutic areas, including gene therapy for genetic deafness and anti-obesity medications, which, if approved, could boost revenue and earnings, while its dividend and share buyback program demonstrate a commitment to returning capital to shareholders.
See More
Sanofi's Nuvaxovid Vaccine Phase 4 Trial Success
- Clinical Trial Success: Sanofi announced that its Nuvaxovid COVID-19 vaccine met the primary endpoint in a phase 4 trial, demonstrating the vaccine's efficacy and safety, which strongly supports the company's competitive position in the vaccine market.
- Market Potential Boost: The successful trial results not only enhance Sanofi's market position in the COVID-19 vaccine sector but also have the potential to drive sales growth in the global vaccine market, especially amid ongoing vaccine demand.
- R&D Investment Returns: Sanofi's continued investment in vaccine development has paid off, with the successful clinical trial laying the groundwork for future product line expansions and new vaccine developments, further solidifying the company's innovative capabilities.
- Strategic Implications: This successful clinical trial presents new opportunities for Sanofi's role in global public health crises, potentially fostering collaborations with governments and international organizations, thereby enhancing its brand image and market influence.
See More
MODERNA: EC APPROVES MARKETING AUTHORIZATION FOR MRNA-1083 FOR PEOPLE AGED 50 AND ABOVE
- Moderna's Authorization: Moderna has received market authorization for its mRNA-1083 vaccine for individuals aged 50 years and older.
- Target Demographic: The vaccine is specifically aimed at older adults, addressing their unique health needs.
See More
MODERNA: MCOMBRIAX TO BE RELEASED IN THE EUROPEAN UNION, PENDING NATIONAL REGULATORY AND ACCESS REQUIREMENTS
Availability in Europe: Moderna's new vaccine, MCOMBRIAX, will be made available in the European Union.
Regulatory Compliance: The vaccine's release is subject to national regulatory and access procedures.
See More
MODERNA'S MRNA COMBINATION VACCINE MCOMBRIAX APPROVED FOR MARKETING BY EUROPEAN COMMISSION FOR INFLUENZA AND COVID-19
Marketing Authorization Granted: Moderna has received marketing authorization from the European Commission for its mRNA combination vaccine, Combrixa.
Targeted Diseases: The vaccine is designed to protect against both influenza and COVID-19.
See More
Moderna's mCOMBRIAX Vaccine Receives EU Approval
- Vaccine Approval: Moderna's mCOMBRIAX (mRNA-1083) vaccine has received marketing authorization from the European Commission, targeting both COVID-19 and influenza, particularly for individuals aged 50 and older, marking a significant advancement in the company's vaccine development efforts.
- Broad Coverage: The approval applies across all 27 EU member states, as well as Iceland, Liechtenstein, and Norway, indicating its wide applicability in the European market and is expected to significantly enhance Moderna's competitiveness in the vaccine sector.
- Expert Recommendation: This approval follows a recommendation from an expert panel of the European Medicines Agency (EMA) in February, reflecting the vaccine's scientific efficacy and safety, thereby laying a solid foundation for Moderna's future sales.
- Market Launch Plans: Moderna stated it will engage with national healthcare officials to plan the launch of mCOMBRIAX in the EU, although the specific timeline will depend on local regulatory and access procedures, a strategy that will impact its market penetration in Europe.
See More
Investment Opportunities in Biotech Stocks
- Moderna's Innovative Potential: Moderna's mRNA vaccine platform allows for faster vaccine design compared to traditional methods, which could drive long-term returns, especially given the increased uncertainty in the COVID-19 vaccine market, where the company's deep pipeline and innovative technology may yield significant investment returns.
- Diverse Pipeline Products: Moderna is developing a vaccine for norovirus and a personalized cancer vaccine, mRNA-4157, which has shown significant potential in mid-stage trials to reduce recurrence and death risk in melanoma patients, further enhancing its market competitiveness.
- Regeneron's Market Leadership: Regeneron's Dupixent is a top-selling drug globally, particularly after gaining important label expansions for COPD treatment, expected to continue driving sales growth, while its high-dose Eylea offers a more patient-friendly dosing regimen, attracting patients despite biosimilar competition.
- Diversified Product Pipeline: Regeneron is developing products across various therapeutic areas, including gene therapy for genetic deafness and anti-obesity medications, which, if approved, could boost revenue and earnings, while its dividend and share buyback program demonstrate a commitment to returning capital to shareholders.
See More
Sanofi's Nuvaxovid Vaccine Phase 4 Trial Success
- Clinical Trial Success: Sanofi announced that its Nuvaxovid COVID-19 vaccine met the primary endpoint in a phase 4 trial, demonstrating the vaccine's efficacy and safety, which strongly supports the company's competitive position in the vaccine market.
- Market Potential Boost: The successful trial results not only enhance Sanofi's market position in the COVID-19 vaccine sector but also have the potential to drive sales growth in the global vaccine market, especially amid ongoing vaccine demand.
- R&D Investment Returns: Sanofi's continued investment in vaccine development has paid off, with the successful clinical trial laying the groundwork for future product line expansions and new vaccine developments, further solidifying the company's innovative capabilities.
- Strategic Implications: This successful clinical trial presents new opportunities for Sanofi's role in global public health crises, potentially fostering collaborations with governments and international organizations, thereby enhancing its brand image and market influence.
See More
